Celyad Oncology (Celyad Oncology) Price-to-Tangible-Book : 33.33 (As of Apr. 27, 2024)

View and export this data going back to 2015. Start your Free Trial

What is Celyad Oncology Price-to-Tangible-Book?

As of today (2024-04-27), Celyad Oncology's share price is $0.60. Celyad Oncology's Tangible Book per Share of Jun. 2023 for the quarter that ended in Jun. 2023 was $0.02. Hence, Celyad Oncology's Price to Tangible Book Ratio of today is 33.33.

The historical rank and industry rank for Celyad Oncology's Price-to-Tangible-Book or its related term are showing as below:

CYADY' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 3.31 Med: 11.25 Max: 93.04
Current: 15

During the past 12 years, Celyad Oncology's highest Price to Tangible Book Ratio was 93.04. The lowest was 3.31. And the median was 11.25.

CYADY's Price-to-Tangible-Book is ranked worse than
94.43% of 1220 companies
in the Biotechnology industry
Industry Median: 2.65 vs CYADY: 15.00

A closely related ratio is called PB Ratio. As of today, Celyad Oncology's share price is $0.60. Celyad Oncology's Book Value per Sharefor the quarter that ended in Jun. 2023 was $0.05. Hence, Celyad Oncology's P/B Ratio of today is 12.24.

Celyad Oncology Price-to-Tangible-Book Historical Data

The historical data trend for Celyad Oncology's Price-to-Tangible-Book can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Celyad Oncology Price-to-Tangible-Book Chart

Celyad Oncology Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Price-to-Tangible-Book

Get a 7-Day Free Trial

9.81

13.87

9.79

3.04

Celyad Oncology Quarterly Data
	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Price-to-Tangible-Book	Get a 7-Day Free Trial															9.79	93.33	-	3.04	22.22

Competitive Comparison of Celyad Oncology's Price-to-Tangible-Book

For the Biotechnology subindustry, Celyad Oncology's Price-to-Tangible-Book, along with its competitors' market caps and Price-to-Tangible-Book data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Celyad Oncology's Price-to-Tangible-Book Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Celyad Oncology's Price-to-Tangible-Book distribution charts can be found below:

* The bar in red indicates where Celyad Oncology's Price-to-Tangible-Book falls into.

Celyad Oncology Price-to-Tangible-Book Calculation

Celyad Oncology's price-to-tangible-book ratio for today is calculated as:

Price to Tangible Book	=	Share Price	/	Tangible Book per Share (Q: Jun. 2023 )
	=	0.60	/	0.018
	=	33.33

It can also be calculated from the numbers for the whole company:

Price to Tangible Book	=	Market Cap	/	Tangible Equity
	=	Market Cap	/	(Total Stockholders Equity	-	Preferred Stock	-	Intangible Assets)

A closely related ratio is called PB Ratio. The difference between Price-to-Tangible-Book Ratio and PB Ratio is that book value other than intangibles are used in the calculation.

Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The Price-to-Book Ratio does not work well for these companies. Some companies even have negative equity, so the Price-to-Book Ratio cannot be applied to them.

Celyad Oncology Price-to-Tangible-Book Related Terms

Thank you for viewing the detailed overview of Celyad Oncology's Price-to-Tangible-Book provided by GuruFocus.com. Please click on the following links to see related term pages.

Celyad Oncology (Celyad Oncology) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Celyad Oncology SA (OTCPK:CYADY) » Definitions » Price-to-Tangible-Book

Comparable Companies

Traded in Other Exchanges

CYAD:Belgium

Address

Rue Edouard Belin 2, Axis Business Park, Brabant Wallon, Mont-Saint-Guibert, BEL, 1435

Website

https://www.celyad.com

Celyad Oncology SA is a biopharmaceutical company focused on the discovery and development of innovative technologies for chimeric antigen receptor T-cell (CAR T) therapies. The company focuses on solid tumors and hematological malignancies. The firm has CYAD-01 and CYAD-02 programs in the pipeline. The company owns trademarks and service marks including CELYAD, C-CATH, C_CURE, CAR-T Cell, THINK, CYAD01 - Deplethink, CYAD02 - Cycle1, CwalityCAR, CYAD-101, and new engagers. The firm has Cardiology and Immuno-oncology operating segments.